https://www.nasdaq.com/press-release/adverum-biotechnologies-granted-orphan-drug-designation-by-fda-for-gene-therapy
https://www.nasdaq.com/press-release/adverum-biotechnologies-provides-advm-022-development-update-and-anticipated
https://www.nasdaq.com/press-release/adverum-biotechnologies-appoints-rupert-dsouza-ph.d.-m.b.a.-as-chief-financial
https://www.nasdaq.com/press-release/adverum-reports-third-quarter-2021-results-2021-11-04
https://www.nasdaq.com/press-release/adverum-presents-clinical-data-on-advm-022-at-the-american-society-of-retina
https://www.nasdaq.com/press-release/adverum-presents-2-year-optic-data-demonstrating-sustained-durability-and-promising
https://www.nasdaq.com/press-release/adverum-to-present-data-from-advm-022-clinical-trials-at-upcoming-medical-conferences
https://www.nasdaq.com/press-release/adverum-appoints-global-regulatory-leader-jim-wang-ph.d.-as-senior-vice-president
https://www.nasdaq.com/press-release/adverum-reports-second-quarter-2021-results-2021-08-05
https://www.nasdaq.com/press-release/adverum-provides-update-on-advm-022-and-the-infinity-trial-in-patients-with-diabetic
https://www.nasdaq.com/press-release/adverum-announces-appointment-of-jon-williams-ph.d.-as-vice-president-clinical
https://www.nasdaq.com/press-release/adverum-announces-changes-to-management-team-2021-06-24
https://www.nasdaq.com/press-release/adverum-appoints-cmo-and-cso-2021-06-01
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-comments-on-preliminary-voting-results-of-adverum-annual
https://www.nasdaq.com/press-release/adverum-stockholders-re-elect-all-adverum-director-nominees-at-2021-annual-meeting
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-issues-statement-to-adverum-stockholders-2021-05-13
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-reminds-adverum-stockholders-to-vote-for-its-three-independent
https://www.nasdaq.com/press-release/adverum-issues-statement-regarding-upcoming-annual-meeting-of-stockholders-2021-05-10
https://www.nasdaq.com/press-release/adverum-reports-first-quarter-2021-results-2021-05-06
https://www.nasdaq.com/press-release/glass-lewis-joins-iss-in-recommending-adverum-shareholders-vote-for-all-three
https://www.nasdaq.com/press-release/iss-recommends-adverum-stockholders-vote-to-elect-sonics-three-independent-highly
https://www.nasdaq.com/press-release/adverum-biotechnologies-presents-long-term-data-through-march-10-2021-from-the-optic
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-comments-on-adverum-biotechnologies-update-regarding-infinity
https://www.nasdaq.com/press-release/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-issues-presentation-correcting-adverums-misstatements-2021-04
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-issues-presentation-detailing-compelling-case-for-immediate
https://www.nasdaq.com/press-release/adverum-files-investor-presentation-highlighting-significant-strategic-progress-and
https://www.nasdaq.com/press-release/adverum-mails-letter-to-stockholders-highlighting-world-class-board-of-directors
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-files-definitive-proxy-statement-and-sends-letter-to
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-new-data-from-the-optic-trial-of-advm-022
https://www.nasdaq.com/press-release/adverum-files-definitive-proxy-materials-and-mails-letter-to-stockholders-detailing
https://www.nasdaq.com/press-release/the-sonic-fund-ii-l.p.-files-preliminary-proxy-statement-relating-to-the-election-of
https://www.nasdaq.com/press-release/adverum-announces-senior-appointments-for-patient-access-and-clinical-operations-as
https://www.nasdaq.com/press-release/adverum-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-03-18
https://www.nasdaq.com/press-release/adverum-announces-board-slate-for-2021-annual-meeting-and-reiterates-commitment-to
https://www.nasdaq.com/press-release/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022
https://www.nasdaq.com/press-release/adverum-to-host-conference-call-and-webcast-to-highlight-updated-advm-022-development
https://www.nasdaq.com/press-release/adverum-appoints-esteemed-healthcare-executive-reed-v.-tuckson-m.d.-to-board-of
https://www.nasdaq.com/press-release/adverum-appoints-christopher-j.-derespino-as-chief-business-officer-2021-02-18
https://www.nasdaq.com/press-release/adverum-to-present-data-from-the-optic-phase-1-trial-with-advm-022-intravitreal-gene
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-publication-of-preclinical-long-term-safety-data-on
https://www.nasdaq.com/press-release/adverum-biotechnologies-completes-patient-enrollment-for-infinity-phase-2-trial-of
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-new-gmp-gene-therapy-manufacturing-facility-2021-01
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-at-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/adverum-biotechnologies-appoints-pharmaceutical-industry-veteran-dawn-svoronos-to
https://www.nasdaq.com/press-release/adverum-biotechnologies-presents-at-the-piper-sandler-annual-virtual-healthcare
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-positive-interim-data-from-cohorts-1-4-from-optic-0
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-recent-business-progress-and-third-quarter-2020
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-new-data-from-the-optic-phase-1-trial-of-advm-022
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-appointment-of-christopher-j.-morrison-ph.d.-as
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-participate-in-the-cantor-virtual-global-healthcare
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-closing-of-%24217-million-public-offering-of-common
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-pricing-of-public-offering-of-common-stock-2020-08
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-%24200-million-public-offering-of-common-stock-2020
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-positive-interim-data-from-cohorts-1-4-from-optic
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-second-0
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-appointment-of-thomas-kochy-as-vice-president
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-first-patient-randomized-in-phase-2-infinity-trial
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-completion-of-patient-dosing-in-cohort-4-of-the
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-appointment-of-heikki-jouttijarvi-as-vice-president
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-leadership-transition-2020-06-15
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-participate-in-goldman-sachs-41st-annual-global-healthcare
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-new-infinity-phase-2-trial-for-advm-022-in-diabetic
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-first-quarter
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-positive-interim-data-from-cohorts-1-3-of-optic-phase
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-virtual-presentations-of-data-through-asgct-and
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-present-new-data
https://www.nasdaq.com/press-release/adverum-biotechnologies-doses-first-patient-in-cohort-4-of-optic-phase-1-clinical
https://www.nasdaq.com/press-release/adverum-biotechnologies-appoints-ophthalmology-industry-veteran-scott-whitcup-m.d.-to
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-recent-business-progress-and-fourth-quarter-2019
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-data-presentations-at-arvo-2020-2020-03-11
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-fourth
https://www.nasdaq.com/press-release/adverum-biotechnologies-appoints-angela-thedinga-as-chief-technology-officer-2020-02
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-at-upcoming-investor-conferences-2020-02-19
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-closing-of-%24150-million-public-offering-of-common
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-pricing-of-public-offering-of-common-stock-2020-02
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-%24100-million-public-offering-of-common-stock-2020
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-new-interim-data-from-cohorts-1-and-2-of-optic-phase
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-additional-data-from-the-optic-phase-1-trial-with
https://www.nasdaq.com/press-release/adverum-biotechnologies-moves-to-new-headquarters-and-expands-laboratory-space-in
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-continued-momentum-with-optic-trial-for-advm-022
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-additional-clinical-data-from-first-cohort-of-optic-0
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-at-upcoming-conferences-2019-12-18
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-participate-in-piper-jaffrays-31st-annual-healthcare
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-recent-business-progress-and-third-quarter-2019
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-host-a-conference-call-and-webcast-to-report-third-quarter
https://www.nasdaq.com/press-release/adverum-biotechnologies-expands-leadership-team-with-the-appointment-of-peter
https://www.nasdaq.com/press-release/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical
https://www.nasdaq.com/press-release/adverum-biotechnologies-announces-data-presentations-at-the-european-society-of-gene
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-additional-clinical-data-from-first-cohort-of-optic
https://www.nasdaq.com/press-release/adverum-biotechnologies-to-present-additional-clinical-data-from-first-cohort-of
https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-positive-24-week-data-from-first-cohort-of-optic
https://www.nasdaq.com/press-release/adverum-biotechnologies-present-new-preclinical-data-advm-022-gene-therapy-wet-amd
https://www.nasdaq.com/press-release/adverum-biotechnologies-provides-clinical-program-update-advm-022-gene-therapy-wet
https://www.nasdaq.com/press-release/adverum-biotechnologies-appoints-ophthalmology-industry-veteran-aaron-osborne-mbbs
https://www.nasdaq.com/press-release/adverum-biotechnologies-participate-upcoming-conferences-2019-04-21
